1. Is Avoidance of Genotoxic Intermediates/Impurities Tenable for Complex, Multistep Syntheses?
2. Analytical advances in pharmaceutical impurity profiling
3. U.S. Department of Health and Human Services Food and Drug Administration. ICH Guidance for Industry: Q3A Impurities in New Drug Substances, June 2008.
4. International Conference on Harmonization, ICH Q3A(R2): Impurities in new drug substances. Step 4, October 2006.
5. International Conference on Harmonization, ICH Q3C(R5): Guideline for residual solvents. Step 4, February 2011.